QIAGEN exceeds outlook for Q1 2023 with 12% CER sales growth in non-COVID product portfolioGlobeNewsWire • 05/03/23
QIAGEN welcomes U.S. Preventive Services Task Force reaffirmation for latent TB screening in populations at increased riskGlobeNewsWire • 05/03/23
QIAGEN launches QIAstat-Dx in Japan with respiratory panel for syndromic testingGlobeNewsWire • 04/24/23
QIAGEN showcases latest technologies to advance cancer research at AACR Annual Meeting 2023GlobeNewsWire • 04/14/23
QIAGEN receives approval for its net-zero carbon emissions target by Science Based Targets initiative (SBTi)GlobeNewsWire • 03/27/23
QIAGEN and Servier Partner to Develop Companion Diagnostic for Acute Myeloid Leukemia (AML) Therapy DrugBusiness Wire • 03/09/23
QIAGEN and SOPHiA GENETICS Forge Partnership to Combine Strengths in Next-Generation SequencingBusiness Wire • 03/01/23
SOPHiA GENETICS and QIAGEN Forge Partnership to Combine Strengths in Next-generation SequencingBusiness Wire • 03/01/23
QIAGEN's tuberculosis blood test QuantiFERON-TB Gold Plus gains CE-marking under new EU IVDR frameworkBusiness Wire • 02/14/23
QIAGEN Exceeds Outlook for Fourth Quarter and Full-Year 2022 With 14% CER Sales Growth in FY 2022 From Non-COVID Product GroupsBusiness Wire • 02/07/23